Abstract
This study aims to investigate clinical significance of topoisomerase 2A (TOP2A) expression and TOP2A gene change in operable invasive breast cancer. This is a retrospective analysis, which includes 256 patients diagnosed as operable invasive breast cancer. All postoperational waxed specimens were subjected to resectioning for staining. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), KI-67, TOP2A expression, and TOP2A gene changes were detected by immunohistochemistry (IHC) and fluorescent in situ hybridization technique (FISH), respectively. Correlation between TOP2A expression and clinicopathological characteristics was also investigated. Effects of TOP2A protein or gene changes on survival rate were detected. Results indicated that 165 were TOP2A positive (64.5 %), and 31 were gene amplification positive (12.1 %). Positive rate of TOP2A expression showed significant correlations with ER, KI-67, and HER-2. The difference of 5-year overall survival (OS) between TOP2A-positive and TOP2A-negative groups did not reach statistical significance (OS: P = 0.321, 85.9 vs. 79.6 %; disease-free survival [DFS]: P = 0.247, 83.3 vs. 75.3 %). Five-year OS in TOP2A amplification group was 68.8 %, which is lower than deficiency and control group (P > 0.05). Subgroup analysis showed no significant differences of OS and DFS either between TOP2A-positive and TOP2A-negative groups or between TOP2A amplification and control group in population of patients with HER-2 amplification, triple negative breast cancer, or hormone-positive breast cancer. In conclusion, positive rate of TOP2A expression correlates significantly with ER, KI-67, and HER-2. However, prognostic significance of either TOP2A expression or TOP2A gene changes in breast cancer and its various subtypes is limited.
Similar content being viewed by others
Reference
Lan J, Huang HY, Lee SW, Chen TJ, Tai HC, Hsu HP, et al. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumor Biol. 2014;35(1):179–87.
Zaczek A, Welnicka-Jaskiewicz M, Bielawski KP, Jaskiewicz J, Badzio A, Olszewski W, et al. Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol. 2008;134(2):271–9.
Sherman-Baust CA, Kuhn E, Valle BL. Shih Iem, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I. A genetically, engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol. 2014;233(3):228–37.
Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, et al. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res. 2010;70(22):8994–9002.
Moiseyenko VM, Volkov NM, Suspistin EN, Yanus GA, Iyevleva AG, Kuligina ES, et al. Evidence for predictive role of BRCA1 and Qtubiii in gastric cancer. Med Oncol. 2013;30(2):545.
Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM, et al. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2012;134(2):549–60.
Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E. Doughty, Edwards J. Comparison of visual and automated assessment of KI-67 proliferation and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer. 2012;106(2):383–8.
Cortesi L, Marcheselli L, Guarneri V, Cirilli C, Braghiroli B, Toss A, et al. Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. Int J Cancer. 2013;132(2):E58–65.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. KI-67 index, HER-2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–23.
Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase-II. Cancer Res. 2007;67(15):7078–81.
Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 2010;16:2391–401.
Romero A, Martín M, Cheang MC, Lopez-Asenjo JA, Oliva B, He X, et al. Assessment of topoisomerase II status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol. 2011;178(4):1453–60.
Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med. 2012;10(1):10.
O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, et al. Topoisomerase II and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101(9):644–50.
Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase II_ gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J ClinPathol. 2005;123(6):889–95.
Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM. Topoisomerase II-gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat. 2006;98(3):337–42.
Zaczek AJ, Markiewicz A, Seroczynska B, Skokowski J, Pienkowski T, Olszewski WP, et al. Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer. Oncologist. 2012;17(10):1246–55.
Wang YX, Fan Y, Zhang Q. Expression of topomerase IIα protein in different molecular subtypes of breast cancer and their prognostic values. Chin J Clin Oncol. 2012;39(7):382–7.
Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, et al. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med. 2012;10(1):212.
Engstrøm MJ, Ytterhus B, Vatten LJ, Opdahl S, Bofin AM. TOP2A gene copy number change in breast cancer. J ClinPathol. 2014;67(5):420–5.
Panousis D, Patsouris E, Lagoudianakis E, Pappas A, Kyriakidou V, Voulgaris Z, et al. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors. Eur J Gynaecol Oncol. 2011;32(2):156–9.
Liu F, Liu Y, He C, Tao L, He X, Song H, et al. Increased MTHFD2 expression is associated with poor prognosis in breast cancer. Tumor Biol. 2014;35(9):8685–90.
Mrklić I, Pogorelić Z, Ćapkun V, Tomic S. Expression of topoisomerase II-α in triple negative breast cancer. Appl Immunohistochem Mol Morphol. 2014;22(3):182–7.
Martin M, Romero A, Cheang MC, Lopez-Garcia-Asenjo JA, Garcia-Saenz JA, Oliva B, et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat. 2011;128(1):127–36.
Acknowledgments
This work was supported by a grant from the Henan Science and Technology Bureau (No. 132300410213).
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Qiao, JH., Jiao, DC., Lu, ZD. et al. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer. Tumor Biol. 36, 6833–6838 (2015). https://doi.org/10.1007/s13277-015-3390-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-3390-6